Document is current
Any future updates will be listed below
-
Authors
Toale, Katy M. https://orcid.org/0000-0001-5980-7309
Marten, Claire A. https://orcid.org/0000-0002-2237-8317
Crouch, Ashley https://orcid.org/0000-0002-5803-5762
Andersen, Clark R. https://orcid.org/0000-0003-1846-9117
Ullah, Fauzia https://orcid.org/0000-0003-1991-1202
Rojas Hernandez, Cristhiam Mauricio https://orcid.org/0000-0003-3890-3929
-
Funding
Funding for this research was provided by:
National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant (P30CA016672)
- License Information
-
More Information
Article History
Received: 29 October 2025
Accepted: 4 January 2026
First Online: 6 March 2026
Declarations
:
: Cristhiam Mauricio Rojas Hernandez received funding from ANTHOS therapeutics (clinical research funding for Abelacimab versus apixaban for cancer associated thrombosis). The other authors have no competing interests to declare that are relevant to the content of this article.
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of the University of Texas MD Anderson Cancer Center approved this study and the need for informed consent was waived.
